Our mandate is clear: we invest in companies that are part of the Oxford cluster (including the science parks and Saïd Business School), with a special focus on the University’s science departments.
We invest in spinouts at pre-seed and seed stage. Although we invest first, unlike many seed investors we also provide follow-on financing all the way to exit. On occasion, if the link to Oxford is strong, we will invest in existing companies.
We lead rounds and have written cheques as small as £50,000 and as big as £25m+.
To translate your inventions into successful businesses, we'll help get the right talent onto your team, advise on your first PR strategy, connect you with key co-investors and industry players, provide strategic property support, and guide you through critical funding and business milestones – we’re at your side at every stage of your journey.
An ingenious invention tackling a multi-billion £ market opportunity that has the potential to attract the world’s best commercial and technical talent.
Coming in early, sticking around longer and building a sustainable advantage for our companies
Leading seed round into PepGen back in 2018 and participating all the way to IPO.
Providing attractive opportunities to commercialise world‑changing ideas for world-class TALENT
Over 2,000 highly skilled jobs created across the portfolio. Experienced CEOs attracted to the portfolio from around the world.
Creating a channel for technology to impact the world for our SCIENTISTS
Over 3 billion doses of the Oxford vaccine distributed globally, mostly into low- to medium- income countries.
In the service of our companies, supporting and promoting a dynamic ECOSYSTEM
55,000 sq. ft of dedicated lab and start-up space added. Grassroots workspace hub launched for entrepreneurs.
Creating a pipeline of great investment opportunities that de‑risk science at the earliest stages for our INVESTOR PARTNERS
In 2021 alone, Oxford companies raised £1.4bn in funding, representing over 50% of the amount raised by UK spinouts overall.
Delivering a positive return on investment for our SHAREHOLDERS
Base Genomics sold to Exact Sciences, generating one of the largest IRR's for a life sciences deal.